CNS Pharmaceuticals(CNSP) - 2023 Q4 - Annual Report

We will continue to require substantial additional capital to continue our clinical development and commercialization activities. Because successful development of our product candidates is uncertain, we are unable to estimate the actual amount of funding we will require to complete research and development and commercialize our products under development. · whether our plan for clinical trials will be completed on a timely basis; · the costs associated with securing and establishing commercialization and m ...